Document Detail


Monoclonal antibodies and other biologic agents in the treatment of asthma.
MedLine Citation:
PMID:  20065638     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Asthma represents a syndrome of airway inflammatory diseases with complex pathology. The immunologic pathogenesis is being increasingly revealed and provides opportunity for targeted biological intervention. Current experience with immunomodulators as targeted therapy in asthma is described in this literature review. Targeted therapies have included strategies to activate dendritic cells through the TLR-9 receptors, to interrupt the action of T(H)2 cytokines with cytokine blockers and monoclonal antibodies, to promote development of T(H)1 responses, to block IgE mediated pathways and to block TNFalpha. Omalizumab is the only biological therapy that has an approved indication in asthma at this time. An improved understanding of the heterogeneity of asthma should allow for specific targeting of different disease phenotypes specific therapies including immunomodulators.
Authors:
Aidan A Long
Related Documents :
16723708 - Adoptively transferred allergen-specific t cells cause maternal transmission of asthma ...
17124428 - Role of cytokines in allergic airway inflammation.
18717828 - Chronic aspiration shifts the immune response from th1 to th2 in a murine model of asthma.
2200318 - Mucosal inflammation in asthma.
24464968 - Non-invasive assessment of upper and lower airway infection and inflammation in cf pati...
11880188 - Factor(s) released from irradiated b-cll cells induce apoptosis in leukemic lymphocytes.
Publication Detail:
Type:  Journal Article; Review     Date:  2009-05-04
Journal Detail:
Title:  mAbs     Volume:  1     ISSN:  1942-0870     ISO Abbreviation:  MAbs     Publication Date:    2009 May-Jun
Date Detail:
Created Date:  2010-01-12     Completed Date:  2010-06-10     Revised Date:  2013-05-31    
Medline Journal Info:
Nlm Unique ID:  101479829     Medline TA:  MAbs     Country:  United States    
Other Details:
Languages:  eng     Pagination:  237-46     Citation Subset:  IM    
Affiliation:
Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA 02114, USA. aalong@mgh.harvard.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Anti-Idiotypic
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Asthma / immunology,  therapy*
Biological Factors / immunology,  therapeutic use*
Cytokines / antagonists & inhibitors
Dendritic Cells / drug effects*,  immunology
Humans
Immunoglobulin E / immunology
Immunomodulation*
Th2 Cells / drug effects*,  immunology
Toll-Like Receptor 9 / agonists
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Chemical
Reg. No./Substance:
0/Antibodies, Anti-Idiotypic; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Biological Factors; 0/Cytokines; 0/Toll-Like Receptor 9; 0/Tumor Necrosis Factor-alpha; 0/omalizumab; 37341-29-0/Immunoglobulin E
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Second International Conference on Accelerating Biopharmaceutical Development: March 9-12, 2009, Cor...
Next Document:  Golimumab.